lintuzumab

Lintuzumab is a humanized monoclonal antibody that targets CD33, a cell surface antigen expressed on myeloid leukemia blasts and early hematopoietic progenitor cells. It was developed primarily for the treatment of acute myeloid leukemia (AML) and other myeloproliferative diseases. Lintuzumab exerts its effects by binding to CD33 and stimulating antibody-dependent cell-mediated cytotoxicity (ADCC), leading to the destruction of tumor cells expressing this antigen. Additionally, it can induce intracellular signaling upon ligation to CD33, resulting in reduced cytokine secretion by AML cells and recruitment of phosphatases such as Shp-1. The drug has also been investigated as a radioimmunoconjugate when linked with actinium-225 for enhanced anti-leukemic activity through targeted alpha-particle delivery. Despite initial promise in preclinical studies and early clinical trials, development for AML was discontinued after phase IIb trials failed to show improved survival outcomes compared to standard therapy[1][2][5][8].

Brand names

Zamyl

Other names

SGN-33SGN33SGN 33HuM195HuM-195HuM 195